National Research Corporation Announces Fourth Quarter and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
94
National Research Corporation Announces Fourth Quarter and Year-End 2016 Results

LINCOLN, Neb., Feb. 14, 2017 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRCIA ) (NASDAQ: NRCIB ) today announced results for the fourth quarter and year-end 2016.

Fourth Quarter

  • Net New Sales $7.1 million
  • Revenue up 8% to $28.4 million
  • Net Income declined 3% to $5.7 million

Year-End 2016

  • Net New Sales $24.0 million
  • Revenue up 7% to $109.4 million
  • Net Income increased 17% to $20.5 million

Remarking on Company performance, Michael D. Hays, chief executive officer of National Research Corporation said, “An increasing proportion of our revenue is being derived from more contemporary and innovative products which support our rebranding focused on 'Human understanding'--an aspiration to keep us at the forefront of a dynamic healthcare environment.”

Revenue for the quarter ended December 31, 2016, was $28.4 million, compared to $26.4 million for the same quarter in 2015. Net income for the quarter ended December 31, 2016, was $5.7 million, compared to $5.9 million for the quarter ended December 31, 2015. Diluted earnings per share decreased to $0.13 for Class A shares and $0.80 for Class B shares for the quarter ended December 31, 2016, from $0.14 for Class A shares and $0.84 for Class B shares for the quarter ended December 31, 2015. Combined diluted earnings per share (a non-GAAP measure) decreased to $0.23 for the quarter ended December 31, 2016, from $0.24 for the fourth quarter 2015.

Revenue for the year ended December 31, 2016, was $109.4 million, compared to $102.3 million for the same quarter in 2015. Net income for the year ended December 31, 2016, was $20.5 million, compared to $17.6 million for the year ended 2015. Diluted earnings per share increased to $0.48 for Class A shares and $2.88 for Class B shares for the year ended December 31, 2016, from diluted earnings per share of $0.41 for Class A shares and $2.49 for Class B shares for the year ended December 31, 2015. Combined diluted earnings per share (a non-GAAP measure) increased to $0.83 for the year ended December 31, 2016, from $0.71 for the year ended 2015.             Regarding the Company’s financial performance, Kevin Karas, chief financial officer of National Research Corporation, said, “We continue to see positive results from our focus on revenue growth and expanding our operating income margin. Revenue and total contract value growth rates on a year-to-date basis more than doubled over the prior year and operating income increased by 18%. Net income for the fourth quarter of 2016 was lower than the prior year’s fourth quarter due to the $1.1 million pre-tax gain on the sale of our clinical workflow product in 2015.”

The Company also announced that its Board of Directors has declared a quarterly cash dividend of $.10 (ten cents) per Class A share and $.60 (sixty cents) per Class B share payable April 14, 2017, to shareholders of record as of the close of business on March 31, 2017.

A listen-only simulcast of National Research Corporation’s 2016 fourth quarter conference call will be available online at http://edge.media-server.com/m/p/7gyz3aqq  on February 15, 2017, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.

For more than 35 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers’ experiences, preferences, risks and behaviors across the healthcare continuum.             The information discussed within this release includes financial results and projections that are in accordance with accounting principles generally accepted in the United States (GAAP). In addition, certain non-GAAP financial measures have been provided that calculate combined earnings per share based on combined Class A and Class B shares and share equivalents outstanding, respectively. The non-GAAP measures should be read in conjunction with the corresponding GAAP measures and should be considered in addition to, and not as an alternative or substitute for, the measures prepared in accordance with GAAP. Please note that the Company’s non-GAAP measures may be different than those used by other companies.  The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company’s financial information presented in accordance with GAAP.  The non-GAAP financial measures are provided in an effort to provide information that investors may deem relevant to evaluate results from the company's core business operations and to compare the company's performance with prior periods.  The company uses both GAAP and these non-GAAP financial measures for evaluating comparable financial performance against prior periods. 

This press release includes “forward-looking” statements related to the Company that can generally be identified as describing the Company’s future plans, objectives or goals.  Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated.  These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  For further information about the factors that could affect the Company’s future results, please see the Company’s filings with the Securities and Exchange Commission.

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
 
  Three months ended    December  31,   Twelve months ended   December 31,  
    2016       2015   2016       2015  
                             
Revenue $ 28,368     $ 26,365   $ 109,384     $ 102,343  
                             
Operating expenses:                            
Direct expenses   11,836       11,365     45,577       44,610  
Selling, general and administrative   6,619       6,294     28,385       27,177  
Depreciation and amortization   1,079       1,000     4,225       4,109  
Total operating expenses   19,534       18,659     78,187       75,896  
                             
Operating income   8,834       7,706     31,197       26,447  
                             
Other income (expense):                            
Interest income   13       14     47       60  
Interest expense   (31 )     (48 )   (190 )     (220 )
Other, net   189       1,096     302       1,073  
                             
Total other income (expense)   171       1,062     159       913  
                             
Income before income taxes   9,005       8,768     31,356       27,360  
                             
Provision for income taxes   3,280       2,841     10,838       9,750  
                             
Net income $ 5,725     $ 5,927   $ 20,518     $ 17,610  
                             
Earnings Per Share of Common Stock:                            
Basic Earnings Per Share:                            
Class A $ 0.14     $ 0.14   $ 0.49     $ 0.42  
Class B $ 0.82     $ 0.85   $ 2.93     $ 2.52  
Diluted Earnings Per Share:                            
Class A $ 0.13     $ 0.14   $ 0.48     $ 0.41  
Class B $ 0.80     $ 0.84   $ 2.88     $ 2.49  
                             
Weighted average shares and share equivalents outstanding                            
Class A - basic   20,717       20,656     20,713       20,741  
Class B - basic   3,511       3,478     3,505       3,478  
Class A - diluted   21,118       20,936     21,037       20,981  
Class B - diluted   3,569       3,523     3,560       3,522  

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share amounts and par value)
 
  Dec. 31,      Dec. 31,  
  2016      2015  
           
ASSETS
Current Assets:          
Cash and cash equivalents $ 33,021     $ 42,145  
Accounts receivable, net 10,864     9,808  
Income taxes receivable 14     157  
Other current assets 3,166     2,951  
Total Current Assets 47,065     55,061  
           
Property and equipment, net 11,806     11,125  
Goodwill 57,861     57,792  
Other, net 3,892     4,071  
Total Assets $ 120,624     $ 128,049  
           
LIABILITIES AND SHAREHOLDERS’ EQUITY
           
Current Liabilities:          
Accounts payable and accrued expenses $ 3,916     $ 3,394  
Deferred revenue 15,497     14,843  
Accrued compensation 4,543     4,391  
Dividends payable 4,213     18,440  
Income taxes payable 662     701  
Notes payable 2,683     2,402  
Total Current Liabilities 31,514     44,171  
           
Non-Current Liabilities 6,304     9,656  
           
Total Liabilities 37,818     53,827  
           
Shareholders’ Equity:          
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued --     --  
Class A Common stock, $0.001 par value; authorized 60,000,000 shares, issued 25,656,760 in 2016 and 25,592,812 in 2015, outstanding 20,891,069 in 2016 and 20,848,168 in 2015 26     26  
Class B Common stock, $0.001 par value; authorized 80,000,000 shares, issued 4,308,875 in 2016 and 4,271,413 in 2015, outstanding 3,539,931 in 2016 and 3,510,150 in 2015 4     4  
Additional paid-in capital 46,725     44,103  
Retained earnings 71,507     65,313  
Accumulated other comprehensive loss (2,626 )   (2,995 )
Treasury stock (32,830 )   (32,229 )
Total Shareholders’ Equity 82,806     74,222  
Total Liabilities and Shareholders’ Equity $ 120,624     $ 128,049  
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Non-GAAP Combined Earnings Per Share Schedule
(In thousands, except per share data)
 
  Three months ended    December  31,   Twelve months ended   December 31,    
  2016   2015   2016   2015
               
Combined Earnings Per Share        
Basic Earnings Per Share $ 0.23   $ 0.24   $ 0.84   $ 0.72
Diluted Earnings Per Share $ 0.23   $ 0.24   $ 0.83   $ 0.71
                 
Combined weighted average shares and share equivalents outstanding                
Combined - Basic 24,228   24,134   24,218   24,219
Combined - Diluted 24,687   24,459   24,597   24,503

 

Contact: Kevin R. Karas   Chief Financial Officer 402-475-2525

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading